https://www.selleckchem.com/products/ve-822.html
CD19(+) represented the only independent factor predicting lower CIR both in the standard-dose group (HR = 0.32 [0.10-1.00], p = 0.05 and in the intermediate-dose group (HR = 0.11 [0.03-0.40], p = 0.001). When combined, KIT(+) plus CD19(-) conferred the most increased relapse risk (3-year CIR 60%; SE 0.12). Specific KIT-D816, instead of general KITmut, may be incorporated in prognostication model for t(8;21) AML. Combination of CD19 with KIT provides a more definite risk stratification profile for t(8;21) AML. Arterial blood gas analys
Like
Comment
Share